Dermatology medical billing hinges on the lesion-count rule, the biopsy-vs-destruction-vs-excision code family split, and the cosmetic-vs-medically-necessary boundary that general billers cannot navigate. Add Mohs surgery global periods, modifier 25 with same-day procedures, and J-code drug capture — and a single miscoded lesion costs $80–$400. MedFactor delivers dermatology-specific RCM that protects every claim.
From general medical dermatology to Mohs surgery and cosmetic procedures, we tailor billing to the coding rules of every dermatology subspecialty.
Acne, eczema, psoriasis, and actinic damage visits with E/M, biopsy (11102/11104), and destruction (17000/17110) capture per lesion.
Mohs micrographic surgery (17311-17315), excision (11400-11446), and layered repair (12031-12018) with global-period and staged-procedure tracking.
Cosmetic line separation (chemoexfoliation 15780-15793, fillers, neurotoxins) with medically-necessary boundary enforcement.
Atopic dermatitis, infantile hemangiomas, and inherited disorders with age-based E/M and lesion-specific coding.
Tissue pathology (88302-88309) with 26/TC component splits and proper biopsy-to-pathology linkage.
Melanoma (C43) and non-melanoma skin cancer (C44) excision, sentinel lymph node biopsy, and oncologic reconstruction.
A single lesion visit can be billed as a biopsy, a destruction, or an excision plus repair — each with a different code family, lesion-count structure, and cosmetic boundary. This is the largest source of dermatology surgical denials and under-capture.
One dermatology session bills the first lesion as the base code and each additional lesion as an add-on, while cosmetic procedures sit on a separate, patient-pay line.
Dermatology billing is governed by lesion-count add-on rules, the biopsy-vs-destruction-vs-excision split, and the cosmetic boundary that general billing companies cannot navigate effectively.
Additional lesions billed under the first-lesion code (17000) instead of add-on codes 17110/17111, losing per-lesion destruction revenue on every session.
Cosmetic procedures (chemoexfoliation 15780-15793, neurotoxins) billed to insurance instead of placed on the patient-pay cosmetic line, triggering denials and audits.
Shave/punch biopsy (11102-11105) billed as destruction (17000-17250) or vice versa, misrepresenting the procedure and triggering NCCI bundling denials.
Mohs surgery (17311-17315) and excision global periods misapplied, with reconstruction (closure, flaps) bundled or denied as included in the excision.
Same-day E/M billed with a procedure (biopsy, destruction) without modifier 25, denied as bundled into the procedure.
Injected drugs (biologics, methotrexate, bleomycin) billed without the correct J-code or with missing units, losing drug reimbursement on every injection.
Quick reference for the most frequently used codes in dermatology billing and coding.
| Code | Description | Common Use |
|---|---|---|
| 11102 | Shave biopsy, 1st lesion | Tissue sampling |
| 11104 | Punch biopsy, 1st lesion | Tissue sampling |
| 17000 | Destruction premalignant lesion, 1st | Actinic keratosis, basal cell |
| 17110 | Destruction benign lesion, up to 14 | Warts, seborrheic keratosis |
| 17111 | Destruction benign lesion, 15+ | Add-on beyond 14 lesions |
| 17250 | Chemocautery of skin lesion | Chemical destruction |
| 11400 | Excision benign lesion, trunk/arms ≤2cm | Full-thickness excision |
| 12001 | Simple repair, scalp/neck/axillae ≤2.5cm | Closure following excision |
| 15782 | Adjacent tissue transfer / rearrangement | Complex reconstruction |
| 11900 | Intralesional injection, up to 7 lesions | Steroid / bleomycin injection |
| Code | Description | Clinical Context |
|---|---|---|
| L70.x | Acne vulgaris | Acne visits / procedures |
| L72.x | Follicular cysts / lipoma | Benign lesion excision |
| C43.x | Melanoma | Skin oncology excision |
| C44.x | Other malignant neoplasm of skin | BCC / SCC treatment |
| D22.x | Melanocytic nevi | Nevus biopsy / excision |
| L20.x | Atopic dermatitis / eczema | Medical dermatology visits |
| L40.x | Psoriasis | Biologic / injection therapy |
| L57.x | Actinic keratosis | Premalignant destruction |
| L98.x | Other disorders of skin | General dermatology |
| L80.x | Vitiligo | Medical / phototherapy |
| Modifier | Description | Dermatology Application |
|---|---|---|
| 25 | Separate E/M same day | E/M with same-day biopsy / destruction |
| 59 | Distinct procedural service | Biopsy distinct from destruction same session |
| 50 | Bilateral procedure | Bilateral lesion excision / biopsy |
| 51 | Multiple procedures | Multiple excisions / repairs same session |
| LT / RT | Left / Right side | Site-specific lesion identification |
| 22 | Increased procedural service | Unusually large / complex excision |
| E1–E4 | Upper eyelid modifiers | Periorbital lesion identification |
| F1–F9 | Finger modifiers | Acral / digit lesion identification |
Comprehensive revenue cycle management designed specifically for dermatology practices.
Specialty coders handle lesion-count add-ons, biopsy-vs-destruction splits, Mohs global periods, and the cosmetic line with accuracy.
Lesion-count defense, biopsy-vs-destruction corrections, cosmetic-line appeals, and modifier 25/59 documentation for dermatology denials.
Pre-procedure authorization for biologics, Mohs surgery, phototherapy, and complex reconstruction procedures.
Prioritized follow-up on aged destruction, biopsy, and Mohs claims with strategic payer escalation to maximize recovery.
Regular audits focused on lesion-count capture, modifier 25/59/50, Mohs global periods, and the cosmetic-vs-medically-necessary boundary.
Real-time dashboards tracking lesion-destruction volume, Mohs surgery productivity, and cosmetic-vs-medical mix.
Understanding the most common denial reasons is the first step to preventing them on biopsy, destruction, and excision claims.
Additional lesions billed under the first-lesion code (17000) instead of add-ons 17110/17111, losing per-lesion destruction revenue.
Per-lesion add-on sequencing with 17000 base, 17110 for 2nd–14th, 17111 for 15th+.
Cosmetic procedures billed to insurance instead of the patient-pay line, triggering medical-necessity denials and audit risk.
Cosmetic procedures isolated on a separate patient-pay line, never submitted to medical insurance.
Shave/punch biopsy billed as destruction or vice versa, misrepresenting the procedure and triggering NCCI bundling edits.
Procedure-specific code selection (11102-11105 vs 17000-17250) with modifier 59 for distinct same-session biopsy.
Reconstruction after Mohs denied as bundled into the excision when global-period rules and staged-procedure modifiers are misapplied.
Global-period tracking with modifier 58 for staged reconstruction and correct closure / flap coding.
Identifying and plugging these common revenue leakage points can significantly improve your practice's bottom line.
2nd–14th lesion destructions not billed as 17110 add-ons to the 17000 base.
Cosmetic procedures submitted to medical payers and denied, never re-billed to the patient.
Punch/shave biopsy billed under destruction codes, losing biopsy reimbursement.
Injected biologics and chemotherapeutics billed without the correct J-code or units.
See how dermatology-specific revenue cycle management transforms your practice's financial performance.
A structured onboarding process designed to deliver measurable improvements within the first 90 days.
Review of dermatology billing operations, lesion-count capture, cosmetic-line separation, and revenue cycle baseline.
EMR and dermatology-system integration, dedicated dermatology billing team, and payer enrollment verification.
Full billing with real-time claim submission, lesion-count verification, and denial prevention protocols.
Performance review against baseline, workflow optimization, and documented revenue improvement.
How our dermatology-specific approach compares to in-house billing and general medical billing companies.
| Capability | In-House Team | General Billing Co. | MedFactor Dermatology |
|---|---|---|---|
| Lesion-count add-on capture (17110/17111) | Inconsistent | ✕ | ✓ |
| Biopsy vs destruction code-family split | ✕ | ✕ | ✓ |
| Cosmetic-line patient-pay enforcement | Inconsistent | ✕ | ✓ |
| Mohs global-period & modifier 58 tracking | ✕ | ✕ | ✓ |
| Modifier 25 on same-day E/M with procedures | Inconsistent | Partial | ✓ |
| J-code / HCPCS drug capture | Manual | Partial | ✓ |
| Biologic / phototherapy prior auth | Manual | Partial | ✓ |
| Lesion-count capture reporting | ✕ | ✕ | ✓ |
| Dedicated dermatology billing team | ✕ | ✕ | ✓ |
Our team combines deep dermatology billing expertise with the technology and processes to deliver consistent, measurable results for medical, surgical, and cosmetic dermatology practices.
Discover exactly where your dermatology practice is losing revenue. Our no-obligation audit analyzes your lesion-count capture, biopsy-vs-destruction coding, and cosmetic-line compliance.
Real results from dermatology practices that partnered with MedFactor for specialty revenue cycle management.
A Mohs surgery practice was bundling reconstruction into the excision and missing modifier 58 for staged closures. MedFactor implemented global-period tracking and staged-procedure coding, recovering substantial surgical revenue in eight months.
A cosmetic-and-medical dermatology clinic was billing additional lesion destructions under the 17000 base code and submitting cosmetic procedures to insurance. MedFactor isolated the cosmetic line and sequenced add-on 17110/17111 codes, recovering per-lesion revenue.
A multi-site dermatology group was coding punch biopsies as destructions and losing J-code drug capture on biologic injections. MedFactor corrected the biopsy-vs-destruction split and J-code units, recovering biopsy and drug reimbursement across all sites.
No matter where your dermatology practice operates, our team understands the payer landscape and regulatory requirements in your region.
Deep coding knowledge across Medicare, Medicaid, and all major commercial payers for dermatology services.
Cosmetic-vs-medically-necessary boundary enforced correctly across all 50 states and payer policies.
Facility and professional billing coordination across hospital-based Mohs and dermatologic surgery.
State Medicaid pediatric dermatology coverage and age-based coding for atopic dermatitis and hemangiomas.
Common questions from dermatology practices considering MedFactor's specialty RCM services.
The first premalignant lesion destruction is billed as the base code 17000, and each additional lesion up to 14 is billed as add-on 17110, with the 15th and beyond billed as 17111. The lesion-count rule is the core of dermatology destruction billing — billing every lesion as 17000 instead of sequencing add-ons is the most common way destruction revenue is lost. We capture every lesion as the correct add-on code and document lesion counts per session so the full destruction volume is reimbursed.
A biopsy (11102 shave, 11104 punch) removes tissue for pathological diagnosis and is a distinct procedure from a destruction (17000 premalignant, 17110 benign up to 14, 17250 chemocautery), which ablates the lesion without pathology. The two code families are not interchangeable — a punch biopsy cannot be billed as a destruction and vice versa. When both are performed in the same session, modifier 59 (distinct procedural service) is appended to the biopsy so it is not denied as bundled into the destruction. We select the correct code family per the documented procedure and use modifier 59 for same-session distinct biopsy.
Cosmetic procedures — chemoexfoliation (15780-15793), cosmetic neurotoxins, dermal fillers, and purely aesthetic treatments — are never billed to medical insurance. They are placed on a separate patient-pay line with their own charge structure, while medically-necessary procedures (actinic keratosis destruction, melanoma excision, biopsy of suspicious lesions) are submitted to the payer with supporting diagnosis codes (L57 actinic keratosis, C44 non-melanoma skin cancer, C43 melanoma). Mixing cosmetic procedures into a medical claim triggers medical-necessity denials and audit risk. We isolate the cosmetic line entirely from the medical claim.
Destruction codes follow a first-lesion base plus add-on structure. For premalignant lesions, 17000 is the first lesion and 17003 (or 17110 for benign lesions up to 14, 17111 for 15+) is each additional lesion. Biopsy codes (11102/11104 for the first, 11103/11105 for each additional) follow the same pattern. The key is sequencing the first lesion as the base and every subsequent lesion as the correct add-on — not billing all lesions as the base code. We verify the documented lesion count against the procedure note and sequence base plus add-on codes so every lesion is captured.
Modifier 25 is appended to an E/M code (99202-99215) when a significant, separately identifiable evaluation and management service is performed on the same day as a procedure such as a biopsy (11104) or destruction (17000). The E/M must be documented as distinct from the procedure — a separate exam, assessment, and plan beyond the procedure itself. Without modifier 25, the E/M is denied as bundled into the procedure. We verify the documentation supports a separate E/M and append modifier 25 so same-day visits are reimbursed alongside the procedure.
Mohs micrographic surgery (17311-17315) carries a global period, and staged reconstruction (flaps, grafts, adjacent tissue transfer 14000-series / 15780-15793) performed in a subsequent session is billed with modifier 58 (staged or related procedure) so it is not denied as bundled into the original excision. For injected drugs, biologics and chemotherapeutics (such as bleomycin for warts, methotrexate, or biologic agents) must be billed with the correct HCPCS J-code and accurate units per dose — missing the J-code or under-reporting units loses drug reimbursement on every injection. We track Mohs global periods, apply modifier 58 for staged reconstruction, and capture every injected drug with the correct J-code and units.
MedFactor applies the same code-level precision across the full practice spectrum. See how we bill these related specialties.
CPT®, ICD-10, HCPCS, and modifier codes referenced on this page reflect the current code sets and are subject to annual updates — always verify against the current-year fee schedule before submission. KPIs and case-study figures shown are representative benchmarks, not guarantees of individual practice results.
Your dermatology practice deserves billing partners who know lesion-count add-ons, biopsy-vs-destruction coding, the cosmetic line, and Mohs global periods — and code every claim correctly. Let MedFactor show you what specialty RCM can do.